Last updated: February 25, 2026
What is NDC 72603-0192?
NDC 72603-0192 is a specific drug identified in the National Drug Code (NDC) system. The NDC outlines the manufacturer, drug, and packaging details. Based on current data, NDC 72603-0192 corresponds to Varenicline Tartrate Tablets, 0.5 mg and 1 mg, marketed under the brand name Champix/Chantix by Pfizer.
Market Overview
Current Market Size
The global smoking cessation pharmacotherapy market was valued at approximately USD 2.5 billion in 2022. Varenicline accounts for roughly 50% of U.S. prescription volume in this segment, with peak sales around USD 1.2 billion in 2022.
- U.S. prescriptions in 2022: Estimated at 7 million units, with steady growth expected at approx. 5% annually over the next five years.
- Key competitors: Bupropion (Zyban), Nicotine Replacement Therapy (NRT) products.
Market Drivers
- Increasing awareness of smoking-related health risks.
- Regulatory approvals expanding coverage.
- Physician and patient acceptance.
- Expanded use in dual therapy for certain populations.
Key Regions
| Region |
Market Share (2022) |
Growth Rate (2022-2027) |
| United States |
65% |
4-6% |
| European Union |
20% |
4% |
| Other (Asia, LATAM, others) |
15% |
3-5% |
Pricing Landscape
Current Price Points
- Average wholesale price (AWP) per 30-day supply of 0.5 mg tablets: USD 265.
- AWP for 1 mg tablets: USD 255.
Discounted prices via pharmacy benefit managers (PBMs) and entities.
Reimbursement Coverage
- Coverage increased post-2020 NICE guidelines in the UK and CMS updates in the U.S.
- Out-of-pocket costs generally range USD 10-50 depending on insurance.
Patent and Competition
- Patent expiry: 2021 (biosimilar and generic candidates introduced).
- Pfizer has filed patent extensions targeting formulation and delivery system.
Price Trends
| Year |
Average Price Per 30-Day Supply |
Notes |
| 2020 |
USD 285 |
Slightly declining trend due to patent challenges |
| 2022 |
USD 262 |
Market stabilization |
| 2023 |
USD 255 |
Slight decrease, emergence of generics |
| 2024 |
USD 240-250 |
Expected further decline with increased generics |
Future Price Projections
Assumptions
- Patent expiration in 2021 led to generic entries.
- Increased generic competition could reduce prices by 20% annually over the next 3-4 years.
- Price declines may stabilize after generic saturation.
Projected Price Range (2024-2028)
| Year |
Estimated Price Per 30-Day Supply |
Rationale |
| 2024 |
USD 220-240 |
Price reduction continues with generic market entry |
| 2025 |
USD 180-210 |
Increased generic market penetration |
| 2026 |
USD 150-180 |
Market consolidation and increased biosimilar options |
| 2027 |
USD 130-150 |
Fully mature generic environment reduces prices further |
Volume and Revenue Forecast
- Unit volume expected to increase due to broader acceptance and insurance coverage.
- Total revenue projected to decline slightly in nominal terms, but volume growth may offset price decreases.
Strategic Implications
- Pfizer's marketing focus may shift towards biosimilar and alternative delivery systems to maintain market share.
- Competition from other smoking cessation agents will pressure generic price declines.
- Payers’ adoption rates could influence pricing dynamics further.
Key Takeaways
- NDC 72603-0192 (Varenicline) holds a significant market share with a global valuation exceeding USD 2.5 billion.
- Price declines of 20-25% annually are anticipated through 2028 due to generic competition.
- The U.S. remains the primary revenue driver, with prices decreasing from USD 265 to roughly USD 150 per 30-day supply.
- Market growth will depend on increased prescription volume and coverage expansion.
- Competitive landscape shifting towards biosimilars and alternative formulations may impact future pricing.
FAQ
How will patent expirations affect the drug’s price?
Patent expiration in 2021 introduced generics, causing a significant price decline. Future biosimilar entries may sustain downward pressure.
What is the primary driver of market growth?
Growing awareness of smoking risks and expanded insurance coverage increase prescriptions.
Are biosimilars or generics dominant in this segment?
Generics dominate post-patent expiry, with biosimilars targeting future formulations.
How does regional variation influence pricing?
U.S. prices are higher due to rebates and insurance structures; European prices are lower but follow similar trends.
What future innovations could influence pricing?
Alternative delivery systems and combination therapies could reshape market dynamics and pricing strategies.
References
- IQVIA. (2023). Prescription drug market data.
- GlobalData. (2022). Smoking cessation therapeutics market analysis.
- Pfizer. (2023). Corporate filings and patent information.
- NICE. (2020). Guidelines on smoking cessation.
- Centers for Medicare & Medicaid Services (CMS). (2022). Drug coverage updates.
